blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3087182

EP3087182 - METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.01.2020
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  15.02.2019
FormerGrant of patent is intended
Status updated on  27.09.2018
FormerExamination is in progress
Status updated on  04.05.2018
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
[2018/43]
Former [2016/44]For all designated states
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
Inventor(s)01 / ROTHMAN, Jeffrey K.
c/o Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, New York 10065 / US
02 / SCHWARTZ, Gary K.
11 Hidden Oak Road
Briarcliff Manor, New York 10510 / US
 [2016/44]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2019/12]
Former [2016/44]Schiweck, Weinzierl & Koch
European Patent Attorneys
Landsberger Straße 98
80339 München / DE
Application number, filing date14875786.717.12.2014
[2016/44]
WO2014US70970
Priority number, dateUS201361920289P23.12.2013         Original published format: US 201361920289 P
[2016/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015100113
Date:02.07.2015
Language:EN
[2015/26]
Type: A2 Application without search report 
No.:EP3087182
Date:02.11.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 02.07.2015 takes the place of the publication of the European patent application.
[2016/44]
Type: B1 Patent specification 
No.:EP3087182
Date:20.03.2019
Language:EN
[2019/12]
Search report(s)International search report - published on:US29.10.2015
(Supplementary) European search report - dispatched on:EP21.07.2017
ClassificationIPC:C12N15/113
[2018/42]
CPC:
C12N15/1135 (EP,US); A61P35/00 (EP,US); A61P43/00 (EP);
C07K14/003 (US); C12Q1/6886 (US); G01N33/5011 (EP);
G01N33/5082 (EP); G01N33/5748 (US); G01N33/68 (EP);
A61K38/00 (EP,US); C12N2310/11 (EP); C12N2310/3181 (EP,US);
C12N2310/3513 (EP,US); C12N2310/3515 (EP,US); C12N2310/531 (US);
C12N2320/30 (EP,US); C12Q2600/136 (US); C12Q2600/158 (US);
G01N2500/10 (US) (-)
Former IPC [2017/34]C12N15/11, C12N15/113
Former IPC [2016/44]C12N15/11, C07H21/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/44]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KREBS UNTER VERWENDUNG VON PEPTIDNUKLEINSÄUREBASIERTEM WIRKSTOFF[2016/44]
English:METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS[2016/44]
French:MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DU CANCER UTILISANT DES AGENTS À BASE D'ACIDES NUCLÉIQUES DE PEPTIDES[2016/44]
Entry into regional phase21.07.2016National basic fee paid 
21.07.2016Search fee paid 
21.07.2016Designation fee(s) paid 
21.07.2016Examination fee paid 
Examination procedure21.07.2016Examination requested  [2016/44]
12.02.2018Amendment by applicant (claims and/or description)
08.05.2018Despatch of a communication from the examining division (Time limit: M02)
19.06.2018Reply to a communication from the examining division
28.09.2018Communication of intention to grant the patent
29.01.2019Receipt of the translation of the claim(s)
07.02.2019Fee for grant paid
07.02.2019Fee for publishing/printing paid
Divisional application(s)EP19163891.5  / EP3581653
Opposition(s)02.01.2020No opposition filed within time limit [2020/09]
Fees paidRenewal fee
27.12.2016Renewal fee patent year 03
12.12.2017Renewal fee patent year 04
21.12.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.12.2014
AL20.03.2019
CY20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
MK20.03.2019
MT20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
LU17.12.2019
[2022/31]
Former [2021/34]HU17.12.2014
AL20.03.2019
CY20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
MT20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
LU17.12.2019
Former [2021/33]HU17.12.2014
AL20.03.2019
CY20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
LU17.12.2019
Former [2021/26]AL20.03.2019
CY20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
LU17.12.2019
Former [2020/46]AL20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
LU17.12.2019
Former [2020/39]AL20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
MC20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2020/17]AL20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
TR20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2020/13]AL20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
RS20.03.2019
SI20.03.2019
SK20.03.2019
SM20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2020/04]AL20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
RS20.03.2019
SK20.03.2019
SM20.03.2019
BG20.06.2019
GR21.06.2019
IS20.07.2019
PT20.07.2019
Former [2019/51]AL20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
RS20.03.2019
SK20.03.2019
SM20.03.2019
BG20.06.2019
GR21.06.2019
PT20.07.2019
Former [2019/49]AL20.03.2019
EE20.03.2019
FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RO20.03.2019
RS20.03.2019
SK20.03.2019
BG20.06.2019
GR21.06.2019
PT20.07.2019
Former [2019/48]FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RS20.03.2019
BG20.06.2019
GR21.06.2019
PT20.07.2019
Former [2019/39]FI20.03.2019
HR20.03.2019
LT20.03.2019
LV20.03.2019
RS20.03.2019
BG20.06.2019
GR21.06.2019
Former [2019/38]FI20.03.2019
LT20.03.2019
BG20.06.2019
GR21.06.2019
Former [2019/37]FI20.03.2019
LT20.03.2019
GR21.06.2019
Former [2019/33]FI20.03.2019
LT20.03.2019
Documents cited:Search[Y]WO2008043366  (UNIV KOEBENHAVN [DK], et al) [Y] 1-15 * page 14 - page 15; figures 1-11; examples 1-7 *;
 [Y]  - KOPPELHUS U ET AL, "Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain", BIOCONJUGATE CHEMISTRY,, vol. 19, doi:10.1021/BC800068H, ISSN 1043-1802, (20080101), pages 1526 - 1534, (20080723), XP003026360 [Y] 1-15 * table 1 *

DOI:   http://dx.doi.org/10.1021/BC800068H
 [Y]  - KLAUS ALBERTSHOFER ET AL, "Structure-Activity Relationship Study on a Simple Cationic Peptide Motif for Cellular Delivery of Antisense Peptide Nucleic Acid", JOURNAL OF MEDICINAL CHEMISTRY, (20051001), vol. 48, no. 21, doi:10.1021/jm050490b, ISSN 0022-2623, pages 6741 - 6749, XP055074967 [Y] 1-15 * page 6745 - page 6746; figure 2 *

DOI:   http://dx.doi.org/10.1021/jm050490b
 [A]  - JIAXIN HU ET AL, "Inhibiting Gene Expression with Peptide Nucleic Acid (PNA)-Peptide Conjugates That Target Chromosomal DNA +", BIOCHEMISTRY, US, (20070601), vol. 46, no. 25, doi:10.1021/bi700230a, ISSN 0006-2960, pages 7581 - 7589, XP055390173 [A] 1-15 * figure 8; table 1 *

DOI:   http://dx.doi.org/10.1021/bi700230a
International search[XY]  - TORRES et al., "Chemical structure requirements and cellular targeting of microRNA-122 by peptide nudeic acids anti-miRs.", Nucleic Acids Res., (20120000), vol. 40, no. 5, pages 2152 - 67, XP055233667 [X] 1-3, 5, 12 * ; Abstract, pg 2153, col 1 and Table 1 * [Y] 4, 6

DOI:   http://dx.doi.org/10.1093/nar/gkr885
 [Y]  - SHEN et al., "Phospholipid conjugate for intracellular delivery of peptide nucleic acids.", Bioconjug Chem., (20090000), vol. 20, no. 9, pages 1729 - 1736, XP055233669 [Y] 4, 6/4 * ; Abstract, pg 5[according to the posted document], 1st para *

DOI:   http://dx.doi.org/10.1021/bc900048y
 [Y]  - KAIHATSU et al., "Extending recognition by peptide nucleic acids (PNAs): binding to duplex DNA and inhibition of transcription by tail-clamp PNA-peptide conjugates.", Biochemistry, (20030000), vol. 42, no. 47, pages 13996 - 14003, XP002597006 [Y] 6 * ; Abstract, pg 13996, col 2 *

DOI:   http://dx.doi.org/10.1021/BI035194K
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.